NCT02514668 - A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2015

Primary Completion Date

December 2, 2021

Study Completion Date

December 2, 2021

Conditions

Plasma Cell Myeloma

Interventions

DRUG

Isatuximab

"Pharmaceutical form: solution for infusion~Route of administration: intravenous"

Trial Locations (18)

12808

Investigational Site Number 203001, Prague

27707

Investigational Site Number 840010, Durham

33600

Investigational Site Number 250004, Pessac

34295

Investigational Site Number 250005, Montpellier

37232

Investigational Site Number 840001, Nashville

44093

Investigational Site Number 250002, Nantes

44718

Investigational Site Number 840013, Canton

48201

Investigational Site Number 840011, Detroit

53226

Investigational Site Number 840006, Milwaukee

54511

Investigational Site Number 250006, Vandœuvre-lès-Nancy

62500

Investigational Site Number 203002, Brno

63110

Investigational Site Number 840015, St Louis

85054

Investigational Site Number 840003, Scottsdale

86021

Investigational Site Number 250001, Poitiers

94010

Investigational Site Number 250008, Créteil

94117

Investigational Site Number 840004, San Francisco

07601

Investigational Site Number 840005, Hackensack

84112-5550

Investigational Site Number 840002, Salt Lake City